PRIMARY RESEARCH | PUBMED LINKS
DRUG CATEGORY: PEPTIDES+ (WEIGHT LOSS)
DRUG NAME: 5-AMINO-1MQ

• FDA Safety Data Sheet not available (experimental peptide).

• Park J. Exploring NNMT: from metabolic pathways to therapeutic targets. Arch Pharm Res. 2024 [PubMed Link]

• Babula JJ. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024 [PubMed Link]

• Zhang CY. Nicotinamide N-methyltransferase in non-alcoholic fatty liver disease: Mechanistic insights and emerging therapeutic strategies. Arch Biochem Biophys. 2025 [PubMed Link]

• Sun WD. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front Pharmacol. 2024 [PubMed Link]

• Liu JR. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. Biomed Res Int. 2021 [PubMed Link]

• Ruf S. Novel tricyclic small molecule inhibitors of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2022 [PubMed Link]

• Rosenthal A. The role of bioidentical hormone replacement therapy in anti-aging medicine: a review of the literature. Int J Dermatol. 2020 [PubMed Link]

• Ingram CF, Payne KS, Messore M, Scovell JM. Testosterone therapy and other treatment modalities for female sexual dysfunction. Curr Opin Urol. 2020 [PubMed Link]

• Martínez-García A, Davis SR. Testosterone use in postmenopausal women. Climacteric. 2021 [PubMed Link]